vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Virginia National Bankshares Corp (VABK). Click either name above to swap in a different company.

Virginia National Bankshares Corp is the larger business by last-quarter revenue ($15.0M vs $11.0M, roughly 1.4× C4 Therapeutics, Inc.). Virginia National Bankshares Corp runs the higher net margin — 39.7% vs -186.0%, a 225.6% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 3.6%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 7.0%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

United Bankshares, Inc. is a bank holding company dual-headquartered in Charleston, West Virginia and Fairfax, Virginia with operations in West Virginia, Virginia, the District of Columbia, Maryland, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia in the United States. United Bankshares is the parent company of United Bank which comprises nearly 250 offices in eight states. In addition, UBSI is the parent company to subsidiaries George Mason Mortgage, United Brokerage, and Cre...

CCCC vs VABK — Head-to-Head

Bigger by revenue
VABK
VABK
1.4× larger
VABK
$15.0M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+109.2% gap
CCCC
112.8%
3.6%
VABK
Higher net margin
VABK
VABK
225.6% more per $
VABK
39.7%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
7.0%
VABK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
VABK
VABK
Revenue
$11.0M
$15.0M
Net Profit
$-20.5M
$6.0M
Gross Margin
Operating Margin
-210.1%
50.5%
Net Margin
-186.0%
39.7%
Revenue YoY
112.8%
3.6%
Net Profit YoY
40.7%
30.6%
EPS (diluted)
$-0.09
$1.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
VABK
VABK
Q4 25
$11.0M
$15.0M
Q3 25
$11.2M
$14.4M
Q2 25
$6.5M
$14.1M
Q1 25
$7.2M
$14.1M
Q4 24
$5.2M
$14.5M
Q3 24
$15.4M
$13.5M
Q2 24
$12.0M
$12.9M
Q1 24
$3.0M
$13.1M
Net Profit
CCCC
CCCC
VABK
VABK
Q4 25
$-20.5M
$6.0M
Q3 25
$-32.2M
$4.6M
Q2 25
$-26.0M
$4.2M
Q1 25
$-26.3M
$4.5M
Q4 24
$-34.6M
$4.6M
Q3 24
$-24.7M
$4.6M
Q2 24
$-17.7M
$4.2M
Q1 24
$-28.4M
$3.6M
Operating Margin
CCCC
CCCC
VABK
VABK
Q4 25
-210.1%
50.5%
Q3 25
-306.4%
39.4%
Q2 25
-441.0%
38.4%
Q1 25
-402.9%
38.4%
Q4 24
-728.4%
40.3%
Q3 24
-183.9%
41.9%
Q2 24
-178.6%
39.5%
Q1 24
-1060.2%
32.9%
Net Margin
CCCC
CCCC
VABK
VABK
Q4 25
-186.0%
39.7%
Q3 25
-286.4%
31.7%
Q2 25
-402.6%
30.0%
Q1 25
-363.7%
31.9%
Q4 24
-667.8%
31.4%
Q3 24
-160.6%
34.1%
Q2 24
-147.6%
32.3%
Q1 24
-933.2%
27.8%
EPS (diluted)
CCCC
CCCC
VABK
VABK
Q4 25
$-0.09
$1.10
Q3 25
$-0.44
$0.84
Q2 25
$-0.37
$0.78
Q1 25
$-0.37
$0.83
Q4 24
$-0.50
$0.85
Q3 24
$-0.35
$0.85
Q2 24
$-0.26
$0.77
Q1 24
$-0.41
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
VABK
VABK
Cash + ST InvestmentsLiquidity on hand
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$184.2M
Total Assets
$359.1M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
VABK
VABK
Q4 25
$74.6M
Q3 25
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Stockholders' Equity
CCCC
CCCC
VABK
VABK
Q4 25
$256.6M
$184.2M
Q3 25
$154.4M
$177.4M
Q2 25
$174.1M
$170.8M
Q1 25
$195.1M
$166.8M
Q4 24
$216.0M
$160.3M
Q3 24
$242.7M
$165.9M
Q2 24
$247.1M
$154.2M
Q1 24
$258.3M
$152.6M
Total Assets
CCCC
CCCC
VABK
VABK
Q4 25
$359.1M
$1.6B
Q3 25
$265.5M
$1.6B
Q2 25
$296.5M
$1.6B
Q1 25
$319.5M
$1.6B
Q4 24
$349.6M
$1.6B
Q3 24
$376.1M
$1.6B
Q2 24
$381.1M
$1.6B
Q1 24
$398.4M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
VABK
VABK
Operating Cash FlowLast quarter
$-22.1M
$21.3M
Free Cash FlowOCF − Capex
$20.8M
FCF MarginFCF / Revenue
138.2%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
3.58×
TTM Free Cash FlowTrailing 4 quarters
$35.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
VABK
VABK
Q4 25
$-22.1M
$21.3M
Q3 25
$-31.2M
$6.0M
Q2 25
$-12.1M
$6.7M
Q1 25
$-33.3M
$2.1M
Q4 24
$-17.9M
$15.3M
Q3 24
$-24.1M
$15.2M
Q2 24
$-5.0M
$-6.4M
Q1 24
$-18.1M
$3.2M
Free Cash Flow
CCCC
CCCC
VABK
VABK
Q4 25
$20.8M
Q3 25
$-31.6M
$5.9M
Q2 25
$6.7M
Q1 25
$1.8M
Q4 24
$-17.9M
$14.6M
Q3 24
$-24.1M
$15.1M
Q2 24
$-5.2M
$-6.8M
Q1 24
$3.1M
FCF Margin
CCCC
CCCC
VABK
VABK
Q4 25
138.2%
Q3 25
-281.5%
41.0%
Q2 25
47.6%
Q1 25
13.0%
Q4 24
-346.5%
100.4%
Q3 24
-157.2%
111.7%
Q2 24
-43.1%
-53.0%
Q1 24
23.9%
Capex Intensity
CCCC
CCCC
VABK
VABK
Q4 25
3.9%
Q3 25
3.7%
0.5%
Q2 25
0.2%
Q1 25
1.8%
Q4 24
0.1%
5.1%
Q3 24
0.1%
0.9%
Q2 24
1.6%
3.1%
Q1 24
0.0%
0.2%
Cash Conversion
CCCC
CCCC
VABK
VABK
Q4 25
3.58×
Q3 25
1.31×
Q2 25
1.59×
Q1 25
0.47×
Q4 24
3.35×
Q3 24
3.30×
Q2 24
-1.54×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons